Provided by Tiger Fintech (Singapore) Pte. Ltd.

IDEAYA Biosciences

21.67
-0.1900-0.87%
Post-market: 21.670.00000.00%16:20 EDT
Volume:780.06K
Turnover:16.94M
Market Cap:1.90B
PE:-6.00
High:22.01
Open:22.00
Low:21.31
Close:21.86
Loading ...

IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer

PR Newswire
·
10 Feb

IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
31 Jan

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire
·
31 Jan

Here’s Why IDEAYA Biosciences, Inc. (IDYA) Will Double in 2025

Insider Monkey
·
31 Jan

IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events

PR Newswire
·
27 Jan

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

Simply Wall St.
·
26 Jan

Conviction stock-picking drives biotech success: a biotech market review of 2024

LiveWire
·
17 Jan

IDEAYA Biosciences Price Target Maintained With a $61.00/Share by RBC Capital

Dow Jones
·
15 Jan

IDEAYA Biosciences: Robust Pipeline and Financial Stability Drive Buy Rating

TIPRANKS
·
13 Jan

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday as Tech-Driven Gains Falter at Year-End

MT Newswires Live
·
30 Dec 2024

IDEAYA Biosciences: Strategic Partnership and Promising Clinical Data Support Buy Rating

TIPRANKS
·
30 Dec 2024

Ideaya enters license agreement for SHR-4849 with Jiangsu Hengrui

TIPRANKS
·
30 Dec 2024

IDEAYA Biosciences Enters Into Licensing Agreement With Jiangsu Hengrui for Cancer Drug Candidate SHR-4849

MT Newswires Live
·
30 Dec 2024

IDEAYA Biosciences: Strategic Acquisition and Promising Clinical Data Drive Buy Recommendation

TIPRANKS
·
30 Dec 2024

IDEAYA Biosciences (IDYA): A Down Year Presents a Window of Opportunity for Investors

TIPRANKS
·
30 Dec 2024

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors

PR Newswire
·
29 Dec 2024

Hengrui Pharmaceuticals Says Co Signs Shr-4849 Project License Agreement With IDEAYA Biosciences

THOMSON REUTERS
·
29 Dec 2024

BRIEF-Hengrui Pharmaceuticals Signs SHR-4849 Project License Agreement With Ideaya Biosciences

Reuters
·
29 Dec 2024

IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
27 Dec 2024

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire
·
27 Dec 2024